logo
In breakthrough study, scientists watch dementia unfold using live brain cells

In breakthrough study, scientists watch dementia unfold using live brain cells

Time of India01-05-2025

For the first time, a team of researchers have used living human brain tissue to see how dementia unfolds in the brain cells.
"Experts said the new way of studying the disease could make it easier to test new drugs and boost the chances of finding ones that work," The Guardian reported citing a study by researchers from the University of Edinburgh. "In the study, scientists and neurosurgeons in Edinburgh teamed up to show for the first time how a toxic form of a protein linked to Alzheimer's,
amyloid beta
, can stick to and destroy vital connections between brain cells."
Amyloid beta is a sticky protein that plays a big role in dementia, especially Alzheimer's. In a healthy brain, it's cleared out regularly. But sometimes, it starts to pile up and form clumps or plaques between brain cells kind of like unwanted gunk. These clumps mess with how brain cells talk to each other and can trigger inflammation, making things worse over time. This buildup is one of the early signs doctors look for when diagnosing Alzheimer's.
For the study, the researchers collected tiny fragments of health brain tissue from cancer patients who were admitted at the Royal Infirmary of Edinburgh. The collected tissues were put in glass bottles filled with oxygenated artificial spinal fluid and taken to the lab for study. "There, samples were sliced into thin pieces, less than a third of a millimetre thick, and laid out in small dishes. Each piece of
living brain tissue
was kept in a nutrient-rich liquid, inside an incubator at 37C to mimic body temperature," the report says.
The team found that when exposed to the toxic protein, the brain did not attempt to repair damage. "Even small changes in natural levels of amyloid beta – increasing or decreasing – were enough to disrupt brain cells. This suggests that the brain requires a finely tuned sweet spot of the protein to function properly," Dr Claire Durrant, a Race Against Dementia fellow and UK
Dementia Research
Institute emerging leader at the Centre for Discovery Brain Sciences at the University of Edinburgh told the media outlet.
Hope for a cure for dementia?
'The use of living human tissue samples generously donated by people undergoing surgery to remove brain tumours allows scientists to probe how living human brain reacts to toxic proteins produced in Alzheimer's, and in future will allow testing of whether new treatments are effective in human brain," Prof Tara Spires-Jones, group leader at the UK Dementia Research Institute told the media.
This breakthrough will help scientists focus on identifying drugs most likely to prevent the loss of synapses—critical connections that enable communication between brain cells and are essential for healthy brain function. Alzheimer's targets these synapses, and their deterioration is a strong predictor of memory loss and impaired cognitive abilities.
Dementia in the US
Dementia is becoming a major health challenge in the U.S., especially as the population ages. Right now, over 6 million Americans are living with Alzheimer's disease, the most common form of dementia, and that number is expected to double in the next couple of decades. It's not just about forgetting names or where you put your keys; dementia slowly affects thinking, reasoning, memory, and even basic day-to-day functions. It can hit families hard, both emotionally and financially, as care needs increase over time.
What's worrying is that many people still confuse dementia with normal aging, which delays diagnosis and treatment. Scientists are exploring everything from lifestyle changes to experimental drugs that target harmful proteins like amyloid beta and tau.
The goal? Help people with dementia live with dignity and independence for as long as possible. It's a tough journey, but with awareness, compassion, and science, there's hope on the horizon.
Masterclass for Students. Upskill Young Ones Today!– Join Now

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

₹120 to ₹238: This small-cap pharma stock zooms nearly 100% in just 22 sessions. Are you holding it?
₹120 to ₹238: This small-cap pharma stock zooms nearly 100% in just 22 sessions. Are you holding it?

Mint

time12 hours ago

  • Mint

₹120 to ₹238: This small-cap pharma stock zooms nearly 100% in just 22 sessions. Are you holding it?

Multibagger Suven Life Sciences share price in focus: Suven Life Sciences share price has been making significant strides on Dalal Street. Despite frontline indices trading in a narrow range, the biopharmaceutical company has delivered stellar gains to its shareholders in a very short period Over the last 22 trading sessions, Suven Life Sciences has surged from ₹ 120 to ₹ 238 apiece, marking a sharp rise of 98.3%. The stock ended May with an impressive 92% monthly gain — its best performance since December 2020, when it had rallied 95%. Several factors have contributed to this sharp uptrend, with one of the key drivers being the company's recently raised ₹ 857 crore through a preferential issue. In mid-May, the company's board approved the issue of 6.4 crore fully convertible warrants on a preferential basis to promoters and non-promoter entities, each priced at ₹ 134. The funds raised will support various initiatives, including ongoing R&D efforts, clinical trials, general corporate purposes, and the development of a new research facility focused on CNS (central nervous system) therapies. Additionally, investor sentiment remains positive due to the company's strong clinical pipeline. Suven Life Sciences is currently advancing multiple CNS-focused drug candidates through various stages of clinical trials—Phases 1, 2, and 3—for conditions such as Alzheimer's disease, narcolepsy, major depressive disorder, and cognitive impairment. Despite the company's posting widening losses in the March quarter, investors remain optimistic about the company's long-term growth prospects. The company's emphasis on developing novel therapeutics for neurodegenerative disorders and CNS diseases, backed by the new fundraising, reinforces its potential for long-term growth, attracting investor interest. For the March-ending quarter, the company reported a widening of consolidated net loss to ₹ 43.95 crore from ₹ 27 crore in Q4FY24, hit by a dip in revenue and higher expenses. Its consolidated revenue from operations in the quarter under review stood at ₹ 1.47 crore against ₹ 2.39 crore in the year-ago period, it added. Total expenses in the March quarter were higher at ₹ 46.63 crore as compared to ₹ 34.21 crore in the same period a year ago. In fiscal year 2024-25, consolidated net loss widened to ₹ 160.75 crore from ₹ 105.08 crore in the previous fiscal year, while the consolidated revenue from operations in FY25 stood at ₹ 6.66 crore as compared to ₹ 11.69 crore in FY24, the company said. The company, in its earnings filing, said that it continues the R&D programs focused on central nervous system (CNS) disease disorders and granted 20 patents during the period covering the countries of Brazil, Eurasia, Europe, Hong Kong, India, Israel, Japan, Macao, Mexico, New Zealand, Sri Lanka, South Africa, and the USA. Suven, a biopharmaceutical company, is engaged in drug discovery and development of new chemical entities (NCEs) in central nervous system (CNS) disorders targeting unmet medical needs globally. The company has a portfolio of advanced-stage clinical candidates and research programs that are designed for CNS disorders such as Alzheimer's disease (AD), sleep disorders, major depressive disorders (MDD), Parkinson's disease (PD), schizophrenia, pain disorders, and gastrointestinal disorders.

Early exposure to pet dogs may lower kids' risk of eczema: Study
Early exposure to pet dogs may lower kids' risk of eczema: Study

Hans India

time12 hours ago

  • Hans India

Early exposure to pet dogs may lower kids' risk of eczema: Study

New Delhi: Early exposure to pet dogs may lower the risk of developing atopic eczema -- a condition characterised by dry, itchy, and inflamed skin -- among children who are genetically prone to the condition. Eczema is an itchy skin disorder caused by a combination of genetic and environmental effects, but little is known about how the two interact. The findings provide new insights into what could cause eczema in children and how environmental factors may influence genetic risk, experts say. The study did not look at the effect of dog exposure in the treatment of existing eczema, and experts caution that introducing a dog may make symptoms worse in some children. 'We know that genetic make-up affects a child's risk of developing eczema and previous studies have shown that owning a pet dog may be protective, but this is the first study to show how this may occur at a molecular level,' said Sara J. Brown, from the University of Edinburgh. 'More work is needed, but our findings mean we have a chance to intervene in the rise of allergic disease, to protect future generations,' she added. For the research published in Allergy, the team analysed data from 16 European studies to test for interactions between the 24 most significant eczema-associated genetic variants and 18 early-life environmental factors. They applied their findings to an additional 10 studies and used lab modelling tests to assess their results. The first analysis (including 25,339 individuals) showed suggestive evidence for interaction between seven environmental factors (antibiotic use, cat ownership, dog ownership, breastfeeding, elder sibling, smoking, and washing practices) and at least one established genetic variant for eczema, with 14 interactions in total. In the additional analysis (254,532 individuals), dog exposure interacted with a particular genetic risk variant on chromosome 5, near the gene that codes for the interleukin-7 receptor, a protein involved in immune cell function. Lab modelling tests showed that this variant affects the expression of interleukin-7 receptors in human skin cells and that dog exposure modifies the genetic effect of this variant on the development of eczema, essentially providing a protective effect by suppressing skin inflammation.

Rare Doomsday Oarfish, Linked To Earthquake Myths, Spotted In Australia
Rare Doomsday Oarfish, Linked To Earthquake Myths, Spotted In Australia

NDTV

time15 hours ago

  • NDTV

Rare Doomsday Oarfish, Linked To Earthquake Myths, Spotted In Australia

An oarfish, a rare and one of the ocean's longest fish, washed ashore the Ocean Beach near Strahan in Tasmania on Monday. The three-metre-long doomsday fish was discovered by a resident, Sybil Robertson, during a beach walk. Ms Robertson said, "I'm five foot nine, and I've got a reasonable stride, [it was] a good three-and-a-bit paces. It was fantastic. I just knew it was something unusual and weird." She said she wasn't aware of the oarfish until she posted the picture of it on the social media page of Citizen Scientists of Tasmania, as per The Guardian. The post, later shared on Reddit, quickly went viral. Rarely seen metres-long 'doomsday' oarfish washes up on Tasmania's wild west coast by u/CupidStunt13 in news A user commented, "The ocean is very unhappy with humanity's disdain for it." Another wrote, "The world DOES seem to be ending more frequently lately." "Makes sense that they would be 'harbingers of disaster'. It takes a lot of turbulence to force something that far down to the surface. The kind that might cause a tsunami," read a comment. The deep-sea creature is called the king of herrings and is considered a harbinger of danger. It is capable of growing up to eight meters in length and weighs over 400 kg. The discovery of the oarfish is surprising as it lives deep in the ocean, nearly 150 to 500 metres, and is rarely seen or caught. Neville Barrett, a marine ecologist at the University of Tasmania, said, "It's exceptionally unusual to see anything like that. We're just not out there. We're not looking, we're not diving, we're not even fishing in that part of the ocean." Mr Barrett described oarfish as a slow-moving and lazy fish with very little muscle. It usually just floats gently in the water, often in a vertical position, and feeds on plankton. According to an old Japanese belief, oarfish is referred to as the doomsday fish because its appearance near the surface is thought to be a warning of natural disasters. In some cases, people have reported seeing oarfish washing ashore before major earthquakes, especially in Japan. They assume it can sense underwater seismic activity and rise to the surface to warn humans.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store